Erasca (ERAS) Assets (2020 - 2026)
Erasca's (ERAS) quarterly Assets came in at $461.2 million in Q1 2026, down 2.12% YoY from $471.2 million in Q1 2025, and up 16.43% on a QoQ basis from $396.2 million in Q4 2025.
Erasca (ERAS) Assets (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Assets data on file, last reported at $461.2 million in Q1 2026.
- Quarterly Assets fell 2.12% year-over-year to $461.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $461.2 million (down 2.12% YoY) and the FY2025 annual result came in at $396.2 million, down 21.17% from the prior year.
- Assets advanced to $461.2 million in Q1 2026, from $396.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $528.9 million in Q3 2024 to a low of $370.0 million in Q1 2024.
- A 5-year average of $454.5 million and a median of $446.4 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets soared 111.43% — and 2023, when it fell 23.23%.
- Tracing ERAS's Assets over 5 years: stood at $514.9 million in 2022, then slipped by 23.23% to $395.3 million in 2023, then climbed by 27.13% to $502.5 million in 2024, then decreased by 21.17% to $396.2 million in 2025, then increased by 16.43% to $461.2 million in 2026.
- The last three Assets figures came in at $461.2 million (Q1 2026), $396.2 million (Q4 2025), and $420.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 435.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 435.05 Mn |
| Mar 31, 2026 | 461.23 Mn |
| Dec 31, 2025 | 396.15 Mn |
| Sep 30, 2025 | 420.40 Mn |
| Jun 30, 2025 | 445.39 Mn |
| Mar 31, 2025 | 471.24 Mn |
| Dec 31, 2024 | 502.53 Mn |
| Sep 30, 2024 | 528.90 Mn |
| Jun 30, 2024 | 525.74 Mn |
| Mar 31, 2024 | 370.02 Mn |
| Dec 31, 2023 | 395.30 Mn |
| Sep 30, 2023 | 419.41 Mn |
| Jun 30, 2023 | 440.66 Mn |
| Mar 31, 2023 | 467.54 Mn |
| Dec 31, 2022 | 514.91 Mn |
| Sep 30, 2022 | 446.43 Mn |
| Jun 30, 2022 | 444.82 Mn |
| Mar 31, 2022 | 475.47 Mn |
| Dec 31, 2021 | 501.42 Mn |
| Sep 30, 2021 | 521.95 Mn |